Literature DB >> 2412034

Hemodynamic response to chronic ketanserin treatment in essential hypertension.

R Fagard, R Fiocchi, P Lijnen, J Staessen, A Amery.   

Abstract

Ketanserin (120 mg/day) or placebo was given orally to 14 patients with mild to moderate essential hypertension according to a double-blind crossover protocol, each treatment period lasting 6 weeks. Resting intraarterial pressure in the recumbent position was reduced from 150/84 to 141/77 mm Hg; the hypotensive effect persisted throughout an uninterrupted graded exercise test to the point of exhaustion. The hemodynamic effects were similar at rest and during exercise. Overall, systemic vascular resistance decreased by 14%, heart rate fell by 5%, but stroke volume and cardiac output increased. The pressor responses to methoxamine and to phenylephrine were reduced by ketanserin.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2412034     DOI: 10.1097/00005344-198500077-00038

Source DB:  PubMed          Journal:  J Cardiovasc Pharmacol        ISSN: 0160-2446            Impact factor:   3.105


  3 in total

1.  Comparison of ketanserin with captopril in older hypertensives. A double-blind randomised trial.

Authors:  P Meyer; M Safar
Journal:  Drugs       Date:  1988       Impact factor: 9.546

2.  Acute and chronic ketanserin in essential hypertension: antihypertensive mechanisms and pharmacokinetics.

Authors:  R Donnelly; H L Elliott; P A Meredith; J L Reid
Journal:  Br J Clin Pharmacol       Date:  1987-11       Impact factor: 4.335

3.  Ketanserin and the arterial baroreceptor reflex in normotensive subjects.

Authors:  A Berdeaux; A Edouard; K Samii; J F Giudicelli
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.